Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for September 29, 2020

9/28/2020

 
Regulatory Update
 
The FDA accepted a resubmitted BLA for Bluebird Bio’s and Bristol-Myers Squibb’s idecabtagene vicleucel for the treatment of multiple myeloma and set a PDUFA  date for 3/27/2021.
 
The FDA accepted the BLA and the EMA accepted the MAA for UCB’s bimekizumab for the treatment of moderate to severe plaque psoriasis.
 
ADC Therapeutics submitted a BLA for loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
 
The EMA approved Galapagos’ and Gilead’s filgotinib to treat moderate to severe active rheumatoid arthritis.
 
Announced Research Updates
 
Sarepta announced 24-month interim results from four patients in a Phase I/II trial, where microdystrophin gene therapy (SRP-9001) improved their North Star Ambulatory Assessment (NSAA) compared to baseline in four ambulatory Duchenne muscular dystrophy participants between the ages of 4 and 7. SRP-9001 increased micro-dystrophin protein levels at 12-weeks, but Sarepta has not reported levels since that time.
 
Agenus announced that in a 143 patient, Phase II trial, treatment with balstilimab and zalifrelimab resulted in a 22% objective response rate (ORR) in patients with advanced cervical cancer. Agenus announced that in a 160 patient, Phase II trial, treatment with balstilimab resulted in a 14% ORR in patients with advanced cervical cancer.
 
Published Research Updates
 
In a 6-week, 45 patient, Phase II trial, reproxalap ophthalmic solution was non-inferior to prednisone acetate ophthalmic solution with or without  reproxalap ophthalmic solution in reducing anterior chamber inflammatory cell count in noninfectious uveitis patients. 
 
During the first 12-months of a 24-month extension of the Phase II trial, 23 patients continued to improve velocity to stand from supine, to run/walk 10 meters and to climb 4 stairs after 18 total months of treatment. When the outcomes in 46 vamorolone-treated DMD patients were compared to a group of 68 patients in the CINRG Duchenne Natural History Study (corticosteroid-naive, n = 19; corticosteroid-treated, n = 68) over a similar 18-month period, there was no difference in time to stand, but an improvement in the time to run/walk 10 meters and to climb 4 stairs.
 
In a 55 patient, Phase II trial, plinabulin was non-inferior to pegfilgrastim in reducing neutropenia in patients receiving docetaxel chemotherapy.
 
In the 1,032 patient, Phase III, open-label, DANUBE trial, neither durvalumab plus tremelimumab or durvalumab monotherapy improved overall survival compared to standard-of-care chemotherapy in patients with metastatic urothelial carcinoma.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.